An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer.Non-coding RNA · 2026
   Review
2. Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers · 2026
   Review
3. MicroRNA-regulated signaling and tumor microenvironment modulation in lung cancer: mechanistic insights and translational opportunities.Cancer cell international · 2026
   Review
4. The Future of Epigenetics: Emerging Technologies and Clinical Applications.ACS pharmacology & translational science · 2026
   Review
5. The role of microRNAs in modulating Wnt signaling pathway dynamics and their therapeutic implications in non-small cell lung cancer.Discover oncology · 2026
   Review
6. Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026
   Review
7. The crosstalk between MiRNAs and autophagy in leukemia: mechanisms and therapeutic insights.Discover oncology · 2025
   Review
8. Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells.Current gene therapy · 2025
   Review
9. MicroRNAs in metabolism for precision treatment of lung cancer.Cellular & molecular biology letters · 2024
   Review
10. METTL Family in Healthy and Disease.Molecular biomedicine · 2024
    Review
11. MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics.Biological procedures online · 2024
    Review
12. Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer.Pharmaceutics · 2023
    Review
13. The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.International journal of molecular sciences · 2023
    Review
14. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.Cancer gene therapy · 2022
    Article
15. The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.International journal of molecular sciences · 2022
    Review
16. MicroRNA as a Potential Therapeutic Molecule in Cancer.Cells · 2022
    Review
17. Smart Nanotherapeutics and Lung Cancer.Pharmaceutics · 2021
    Review
18. The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer.Cancers · 2021
    Review
19. miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.Cancers · 2021
    Review
20. Recent applications and strategies in nanotechnology for lung diseases.Nano research · 2021
    Review

Corrections and comments

• Comment on
  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.